Allergy Therapeutics (LON:AGY) Issues Earnings Results

Allergy Therapeutics (LON:AGY) released its quarterly earnings results on Monday. The company reported GBX (0.23) ($0.00) earnings per share for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Trading Down 13.2 %

Allergy Therapeutics stock opened at GBX 5.63 ($0.07) on Monday. The stock has a market cap of £276.47 million, a price-to-earnings ratio of -5.42, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. Allergy Therapeutics has a 12 month low of GBX 2.65 ($0.03) and a 12 month high of GBX 8 ($0.10). The business has a 50 day moving average price of GBX 6.62 and a two-hundred day moving average price of GBX 5.89.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.